Nelson Shu-Sang Yee

Nelson Shu-Sang Yee, MD, PhD, RPh is a Professor in the Department of Medicine, Division of Hematology and Oncology at Penn State Cancer Institute. His academic career spans several decades with significant contributions to cancer research, particularly in pancreatic oncology. Affiliated with Penn State College of Medicine, Dr. Yee maintains an active research program focused on pancreatic cancer pathogenesis and treatment.

Dr. Yee's research interests center on pancreatic cancer biology, molecular biomarkers, and novel therapeutic approaches. His work specifically addresses pancreatic adenocarcinoma, receptor signaling pathways, and malignant neoplasms, with strong emphasis on identifying biological markers for cancer detection and treatment response. His research fingerprint shows 100% focus on pancreas cancer, 61% on pancreas adenocarcinoma, and significant contributions to receptor pharmacology (55%) and malignant neoplasm research (54%).

Analysis of Dr. Yee's publication trends from 2015-2025 reveals consistent output with peaks in 2015 (8 publications) and 2019 (6 publications). His recent work (2023-2025) demonstrates expanding focus into immunotherapy, precision oncology, and molecular diagnostics across multiple cancer types while maintaining his pancreatic cancer expertise. The publications span diverse formats including original research articles (52), review articles (14), editorials (4), and other scholarly contributions.

Dr. Yee has secured competitive funding from the National Institute of Diabetes and Digestive and Kidney Diseases for two major research projects: 'Analysis of zebrafish exocrine pancreas development' (2002-2004) and 'Cloning of Zebrafish exocrine pancreas mutant' (2005-2006). These projects focused on pancreatic organogenesis, zebrafish models, and gene function in cellular differentiation.

His laboratory work appears to focus on pancreatic cancer models, particularly using zebrafish for studying exocrine pancreas development and disease mechanisms. Current research directions include granzyme and perforin family genes in multiple cancers, precision oncology implementation, and diagnostic approaches for hepatocellular carcinoma and pancreatic cancer.